Evidence map›Paper›PMID 22254076›Full record

Trial reportNutrients2011

Folate status of reproductive age women and neural tube defect risk: the effect of long-term folic acid supplementation at doses of 140 µg and 400 µg per day.

Nicola A Hursthouse, Andrew R Gray, Jody C Miller, Meredith C Rose, Lisa A Houghton

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Nutrients, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Review
  8. Article
  9. Scientific opinion on the tolerable upper intake level for folate.EFSA journal. European Food Safety Authority · 2023
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Interaction between Metformin, Folate and Vitamin BInternational journal of molecular sciences · 2021
    Review
  15. Review
  16. Observational
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Nicola A HursthouseDepartment of Human Nutrition, University of Otago, Dunedin 9054, New Zealand.
Andrew R GrayDepartment of Preventive and Social Medicine, University of Otago, Dunedin 9054, New Zealand.ORCID 0000-0003-4299-2194
Jody C MillerDepartment of Human Nutrition, University of Otago, Dunedin 9054, New Zealand.
Meredith C RoseDepartment of Human Nutrition, University of Otago, Dunedin 9054, New Zealand.
Lisa A HoughtonDepartment of Human Nutrition, University of Otago, Dunedin 9054, New Zealand.
University of Otago · NZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary prevention of most folate-responsive neural tube defects (NTDs) may not require 400 μg folic acid/day but may be achieved by attaining a high maternal folate status. Using RBC folate ≥906 nmol/L as a marker for NTD risk reduction, the study aimed to determine the change in blood folate concentrations in reproductive age women in response to long-term folic acid supplementation at 400 µg/day and 140 µg/day (dose designed to mimic the average daily folic acid intake received from New Zealand's proposed mandatory bread fortification program). Participants were randomly assigned to a daily folic acid supplement of 140 µg (n = 49), 400 µg (n = 48) or placebo (n = 47) for 40 weeks. RBC folate concentrations were measured at baseline, and after 6, 12, 29 and 40 weeks. At 40 weeks, the overall prevalence of having a RBC folate <906 nmol/L decreased to 18% and 35% in the 400 µg and 140 µg groups, respectively, while remaining relatively unchanged at 58% in the placebo group. After 40 weeks, there was no evidence of a difference in RBC folate between the two treatment groups (P = 0.340), nor was there evidence of a difference in the odds of a RBC folate <906 nmol/L (P = 0.078). In conclusion, the average daily intake of folic acid received from the proposed fortification program would increase RBC folate concentrations in reproductive age women to levels associated with a low risk of NTDs.

Indexed as

Dietary SupplementsAdolescentAdultBreadDouble-Blind MethodErythrocytesFemaleFolic AcidFood, FortifiedHumansNeural Tube DefectsNew ZealandTreatment OutcomeYoung AdultFolic Acidblood folate statusfolic acid fortificationneural tube defectssupplementation

Identifiers

PMID22254076
PMCPMC3257734
OpenAlexW2061570610

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.